Home / Peptides / Elamipretide

Elamipretide (SS-31) Dosage Chart and Schedule

FDA-approved (rare disease)

Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.

Also called: SS-31, Forzinity, MTP-131, Bendavia

Regulatory status (US)

FDA accelerated approval on September 19, 2025 as Forzinity, to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is required. It has no approved use outside Barth syndrome.

What it is

A small four-amino-acid peptide that binds cardiolipin in the inner membrane of mitochondria.

Label dose (Forzinity)

PatientsDoseProduct
Barth syndrome, 30 kg or more40 mg under the skin once daily280 mg / 3.5 mL vial (80 mg/mL)

From the Forzinity label. Supplied as a ready-to-use solution; discard 8 days after first opening.

Elamipretide reconstitution calculator

Enter your vial and your prescribed dose to see the units on a U-100 syringe.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

What human studies show

Safety

Questions

Is Elamipretide FDA-approved?
FDA accelerated approval on September 19, 2025 as Forzinity, to improve muscle strength in people with Barth syndrome who weigh at least 30 kg. A confirmatory trial is required. It has no approved use outside Barth syndrome.
What dose of Elamipretide has been studied?
Barth syndrome, 30 kg or more: 40 mg under the skin once daily: 280 mg / 3.5 mL vial (80 mg/mL). From the Forzinity label. Supplied as a ready-to-use solution; discard 8 days after first opening.
How many units is my Elamipretide dose?
Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.

Related

Tirzepatide

Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.

Semaglutide

Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).

Orforglipron (Foundayo)

Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.

Tesamorelin

GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.

Sources

  1. DailyMed: Forzinity (elamipretide) labeling
  2. Stealth BioTherapeutics: FDA accelerated approval of Forzinity (Sep 2025)
  3. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.